Kalaris Therapeutics Inc. (NASDAQ:KLRS) Short Interest Up 26.1% in December

Kalaris Therapeutics Inc. (NASDAQ:KLRS) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totaling 503,479 shares, an increase of 26.1% from the November 30th total of 399,288 shares. Currently, 10.8% of the shares of the stock are sold short. Based on an average daily volume of 145,440 shares, the short-interest ratio is presently 3.5 days. Based on an average daily volume of 145,440 shares, the short-interest ratio is presently 3.5 days. Currently, 10.8% of the shares of the stock are sold short.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of KLRS. Johnson Financial Group Inc. acquired a new stake in Kalaris Therapeutics during the third quarter worth about $58,000. XTX Topco Ltd purchased a new stake in shares of Kalaris Therapeutics in the 2nd quarter valued at approximately $65,000. Bridgeway Capital Management LLC acquired a new stake in shares of Kalaris Therapeutics during the 3rd quarter worth approximately $130,000. Belpointe Asset Management LLC purchased a new stake in shares of Kalaris Therapeutics during the 3rd quarter valued at approximately $231,000. Finally, Fortis Capital Advisors LLC acquired a new position in Kalaris Therapeutics in the third quarter valued at approximately $231,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on KLRS shares. Raymond James Financial started coverage on shares of Kalaris Therapeutics in a research report on Tuesday, September 2nd. They set a “strong-buy” rating for the company. Citigroup reiterated an “outperform” rating on shares of Kalaris Therapeutics in a research note on Thursday, December 18th. Citizens Jmp began coverage on Kalaris Therapeutics in a research report on Monday, November 3rd. They issued a “market outperform” rating and a $20.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kalaris Therapeutics in a research report on Monday. Finally, Chardan Capital began coverage on Kalaris Therapeutics in a research note on Tuesday, December 23rd. They issued a “buy” rating and a $19.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $14.00.

Kalaris Therapeutics Price Performance

KLRS opened at $8.38 on Wednesday. The company’s 50 day simple moving average is $6.63 and its two-hundred day simple moving average is $4.67. The firm has a market capitalization of $156.71 million, a price-to-earnings ratio of -2.22 and a beta of -0.04. Kalaris Therapeutics has a 1-year low of $2.14 and a 1-year high of $12.90.

Kalaris Therapeutics (NASDAQ:KLRS) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.02.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.